Three-dimensional (3D) DOAMS molds (master) with or without imperfection were designed in SolidWorks (Dassault Systèmes, Vèlizy-Villacoublay, France) and then printed with gray resin on a Form2 3D printer (Formlabs, Somerville, USA) or MicroFine green resin (Protolabs, Maple Plain, USA). A SYLGARD 184 (Dow Inc., Midland, USA) PDMS mold (negative) was fabricated from the master mold by mixing two-part resin systems containing vinyl groups (part A) and hydrosiloxane groups (part B), and the material was cast around the master. After cross-linked network formation, the flexible elastomeric molds were carefully removed. Carbopol 971P NF (Lubrizol, Wickliffe, USA) polymer was dissolved in dimethylformamide under sonication (100 kHz) with a concentration of 25 mg/ml. FITC (5%) was added to the Carbopol solution as an indicator. After weighing and balancing the molds, 200ul of Carbopol solution was added, followed by 10 min of vacuum (600 mmHg) treatment. After centrifugation (2000 rpm for 10 min; Eppendorf AG 22331 Hamburg, Germany), the molds were placed in a desiccator for another 10-min treatment and then placed in a vacuum chamber for 24 hours at 45°C. The casting process was repeated between one and five times. Subsequently, 50 mg of PCL (45 kDa; CAPA 6400, Perstorp) was introduced to the mold, followed by heating to 120°C; the mold was then placed in a vacuum for 3 hours. After cooling to room temperature, the MN arrays were carefully peeled off from the PDMS mold and maintained at room temperature for further applications.
Copyright: Content may be subjected to copyright.
How to cite:
Readers should cite both the Bio-protocol preprint and the original research article where this protocol was used:
Chen, W and Traverso, G(2022). Fabrication of the DOAMS. Bio-protocol Preprint. bio-protocol.org/prep1916.
Chen, W., Wainer, J., Ryoo, S. W., Qi, X., Chang, R., Li, J., Lee, S. H., Min, S., Wentworth, A., Collins, J. E., Tamang, S., Ishida, K., Hayward, A., Langer, R. and Traverso, G.(2022). Dynamic omnidirectional adhesive microneedle system for oral macromolecular drug delivery. Science Advances 8(1). DOI: 10.1126/sciadv.abk1792
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this
article to respond.
0/150
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.
Spinning
Post a Question
0 Q&A
Spinning
This protocol preprint was submitted via the "Request
a Protocol" track.